Inhibition of chymotryptic-like standard proteasome activity exacerbates doxorubicin-induced cytotoxicity in primary cardiomyocytes.

@article{Spur2016InhibitionOC,
  title={Inhibition of chymotryptic-like standard proteasome activity exacerbates doxorubicin-induced cytotoxicity in primary cardiomyocytes.},
  author={Eva-Margarete Spur and Nadine Althof and Dorota Respondek and Karin Klingel and Arnd Heuser and Herman S Overkleeft and Antje Voigt},
  journal={Toxicology},
  year={2016},
  volume={353-354},
  pages={34-47}
}
The anthracycline doxorubicin (DOX) is a potent anticancer agent for multiple myeloma (MM). A major limitation of this drug is the induction of death in cardiomyocytes leading to heart failure. Here we report on the role of the ubiquitin-proteasome system (UPS) as a critical surveillance pathway for preservation of cell vitality counteracting DOX treatment… CONTINUE READING